November 2024
1. HARTER P, Marth C, Mouret-Reynier MA, Cropet C, et al
   Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
   Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.
   

   >> Share

   
   
2. LORUSSO D, Fuca G
   KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer?
   Ann Oncol. 2024;35:925-927.
   

   >> Share

   
   October 2024
3. LORUSSO D, Colombo N, Dubot C, Caceres MV, et al
   Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study.
   Ann Oncol. 2024 Oct 9:S0923-7534(24)04033-X. doi: 10.1016/j.annonc.2024.
   

   >> Share

   
   September 2024
4. MONK BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, et al
   Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
   Ann Oncol. 2024 Sep 14:S0923-7534(24)03762-1. doi: 10.1016/j.annonc.2024.08.2241
   

   >> Share

   
   August 2024
5. VAN GORP T, Cibula D, Lv W, Backes F, et al
   ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer.
   Ann Oncol. 2024 Aug 23:S0923-7534(24)03822-5. doi: 10.1016/j.annonc.2024.08.2242
   

   >> Share

   
   
6. COLOMBO N, Caruso G, Jalving M
   Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story.
   Ann Oncol. 2024;35:686-688.
   

   >> Share

   
   June 2024
7. POWELL MA, Bjorge L, Willmott L, Novak Z, et al
   Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial.
   Ann Oncol. 2024 Jun 10:S0923-7534(24)00721-X. doi: 10.1016/j.annonc.2024.
   

   >> Share

   
   May 2024
8. PIGNATA S, Califano D, Lorusso D, Arenare L, et al
   MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
   Ann Oncol. 2024 May 2:S0923-7534(24)00128-5. doi: 10.1016/j.annonc.2024.
   

   >> Share

   
   February 2024
9. BOGANI G, Monk BJ, Powell MA, Westin SN, et al
   Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
   Ann Oncol. 2024 Feb 29:S0923-7534(24)00056-5. doi: 10.1016/j.annonc.2024.
   

   >> Share

   
   January 2024
10. LEDERMANN JA, Matias-Guiu X, Amant F, Concin N, et al
    ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
    Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023.
    

    >> Share

    
    December 2023
11. MCNEISH IA, Monk BJ
    Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma.
    Ann Oncol. 2023;34:1074-1076.
    

    >> Share

    
    October 2023
12. SESSA C, Paluch-Shimon S
    Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian canc
    Ann Oncol. 2023 Oct 26:S0923-7534(23)04325-9. doi: 10.1016/j.annonc.2023.
    

    >> Share

    
    
13. TJALMA WAA
    There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes.
    Ann Oncol. 2023 Oct 20:S0923-7534(23)04324-7. doi: 10.1016/j.annonc.2023.
    

    >> Share

    
    
14. PUJADE-LAURAINE E, Selle F, Scambia G, Asselain B, et al
    Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
    Ann Oncol. 2023 Oct 3:S0923-7534(23)04007-3. doi: 10.1016/j.annonc.2023.09.3110.
    

    >> Share

    
    August 2023
15. GONZALEZ-MARTIN A, Harter P, Leary A, Lorusso D, et al
    Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    Ann Oncol. 2023 Aug 10:S0923-7534(23)00797-4. doi: 10.1016/j.annonc.2023.
    

    >> Share

    
    
16. LOIBL S, Azim HA Jr, Bachelot T, Berveiller P, et al
    ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).
    Ann Oncol. 2023 Aug 9:S0923-7534(23)00798-6. doi: 10.1016/j.annonc.2023.
    

    >> Share

    
    May 2023
17. RAY-COQUARD I, Leary A, Pignata S, Cropet C, et al
    Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
    Ann Oncol. 2023 May 19:S0923-7534(23)00686-5. doi: 10.1016/j.annonc.2023.
    

    >> Share

    
    December 2022
18. LOVEDAY C, Garrett A, Law P, Hanks S, et al
    Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
    Ann Oncol. 2022;33:1318-1327.
    

    >> Share

    
    November 2022
19. LABIDI-GALY SI, Rodrigues M, Sandoval JL, Kurtz JE, et al
    Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
    Ann Oncol. 2022 Nov 28:S0923-7534(22)04733-0. doi: 10.1016/j.annonc.2022.
    

    >> Share

    
    October 2022
20. SESSA C, Balmana J, Bober SL, Cardoso MJ, et al
    Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04193.
    

    >> Share

    
    August 2022
21. KRISTELEIT RS, Moore K
    Life after SOLO-2: Is Olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi) resistant, recurrent ovarian cancer?
    Ann Oncol. 2022 Aug 11. pii: S0923-7534(22)03867.
    

    >> Share

    
    June 2022
22. FRENEL JS, Kim JW, Aryal N, Asher R, et al
    Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Ann Oncol. 2022 Jun 27. pii: S0923-7534(22)01740.
    

    >> Share

    
    May 2022
23. OAKNIN A, Bosse TJ, Creutzber CL, Giornelli G, et al
    Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2022 May 30. pii: S0923-7534(22)01207.
    

    >> Share

    
    April 2022
24. COLEMAN RL
    For Ovarian Cancer PARPi maintenance therapy: more is better, right?
    Ann Oncol. 2022 Apr 7. pii: S0923-7534(22)00681.
    

    >> Share

    
    February 2022
25. FRANCIS KE, Kim SI, Friedlander M, Gebski V, et al
    The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2022 Feb 24. pii: S0923-7534(22)00338.
    

    >> Share

    
    January 2022
26. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    

    >> Share

    
    
27. MOORE KN, du Bois A
    Homologous recombination deficiency testing in first-line ovarian cancer.
    Ann Oncol. 2022 Jan 8. pii: S0923-7534(22)00004.
    

    >> Share

    
    November 2021
28. VERGOTE I, Gonzalez-Martin A, Ray-Coquard I, Harter P, et al
    European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04828.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share